{"protocolSection":{"identificationModule":{"nctId":"NCT02985463","orgStudyIdInfo":{"id":"2014-402M-MA-§ 23b MPG"},"organization":{"fullName":"Universitätsmedizin Mannheim","class":"OTHER"},"briefTitle":"Left Atrial Appendage Occlusion and Biomarker Evaluation","officialTitle":"Left Atrial Appendage Occlusion and Biomarker Evaluation","acronym":"LABEL"},"statusModule":{"statusVerifiedDate":"2020-08","overallStatus":"UNKNOWN","lastKnownStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-06","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2021-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2016-12-03","studyFirstSubmitQcDate":"2016-12-03","studyFirstPostDateStruct":{"date":"2016-12-07","type":"ESTIMATED"},"lastUpdateSubmitDate":"2020-08-26","lastUpdatePostDateStruct":{"date":"2020-08-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Michael Behnes","investigatorTitle":"Dr. med","investigatorAffiliation":"Universitätsmedizin Mannheim"},"leadSponsor":{"name":"Universitätsmedizin Mannheim","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"\"Left Atrial Appendage Occlusion and Biomarker Evaluation\" (LABEL) is a single-center, prospective and observational study evaluating changes of the expression of biomarkers in eligible patients before and after percutaneous implantation of a left atrial appendage (LAA) occlusion device at mid-term follow-up.","detailedDescription":"This study will evaluate the changes of different types of biomarkers before and after successful percutaneous implantation of an LAA occlusion device.\n\nBiomarker evaluation will focus on blood derived biomarkers including neurohormones, proteins, cytokines, microRNAs and metabolomics."},"conditionsModule":{"conditions":["Stroke","Atrial Fibrillation","Bleeding"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"bioSpec":{"retention":"SAMPLES_WITH_DNA","description":"Two peripheral blood withdraws in EDTA, citrate, ammonium heparin, serum tubes 24 hours before and at mid-term follow up at 6 months after successful LAA occlusion device implantation."},"enrollmentInfo":{"count":60,"type":"ACTUAL"}},"outcomesModule":{"primaryOutcomes":[{"measure":"Biomarker levels before successful LAA occlusion device implantation","timeFrame":"24 hours before intervention"}],"secondaryOutcomes":[{"measure":"Biomarker levels after successful LAA occlusion device implantation","timeFrame":"mid-term follow up at 6 months"},{"measure":"Changes of biomarker expression before and after device implantation over mid-term follow-up, depending of complete, incomplete occlusion, imaging data (transesophageal echocardiography, computed tomography)","timeFrame":"mid-term follow up at 6 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* non valvular atrial fibrillation, that makes anticoagulation to prevent embolic stroke from the LAA\n* contraindication for the therapy with oral anticoagulants:\n* refusal to take oral anticoagulation\n* HasBled-score more than 3\n* prior bleedings under oral anticoagulation\n\nExclusion Criteria:\n\n* under 18 years\n* severely reduced left atrial function\n* mechanical heart valve\n* pulmonary embolism\n* deep vein thrombosis\n* myocardial infarction within the last 3 months\n* electrical cardioversion within 30 days after potential occluder implantation\n* atrial septum defect or interventional/surgical occlusion of ASD\n* status after heart transplant\n* symptomatic carotid artery stenosis\n* transient ischemic attack (TIA) or stroke within last 30 days\n* intracerebral bleeding within the last 2 months\n* acute infection\n* existing or planned pregnancy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients suffering from non valvular atrial fibrillation with a contraindication for oral anticoagulation (i.e. bleeding) being eligible of percutaneous implantation of LAA occlusion devices.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Ibrahim Akin, Prof.","affiliation":"University Medical Center Mannheim","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"University Medical Centre Mannheim","city":"Mannheim","state":"Baden-Württemberg","zip":"68167","country":"Germany","geoPoint":{"lat":49.4891,"lon":8.46694}}]},"referencesModule":{"references":[{"pmid":"27009279","type":"BACKGROUND","citation":"Behnes M, Akin I, Sartorius B, Fastner C, El-Battrawy I, Borggrefe M, Haubenreisser H, Meyer M, Schoenberg SO, Henzler T. --LAA Occluder View for post-implantation Evaluation (LOVE)--standardized imaging proposal evaluating implanted left atrial appendage occlusion devices by cardiac computed tomography. BMC Med Imaging. 2016 Mar 24;16:25. doi: 10.1186/s12880-016-0127-y."},{"pmid":"26822890","type":"RESULT","citation":"Fastner C, Behnes M, Sartorius B, Yildiz M, Mashayekhi K, El-Battrawy I, Lehmann R, Baumann S, Becher T, Borggrefe M, Akin I. Left atrial appendage morphology, echocardiographic characterization, procedural data and in-hospital outcome of patients receiving left atrial appendage occlusion device implantation: a prospective observational study. BMC Cardiovasc Disord. 2016 Jan 28;16:25. doi: 10.1186/s12872-016-0200-z."},{"pmid":"29861102","type":"DERIVED","citation":"Rusnak J, Behnes M, Saleh A, Fastner C, Sattler K, Barth C, Wenke A, Sartorius B, Mashayekhi K, Hoffmann U, Yuecel G, Lang S, Borggrefe M, Akin I. Interventional left atrial appendage closure may affect metabolism of essential amino acids and bioenergetic efficacy. Int J Cardiol. 2018 Oct 1;268:125-131. doi: 10.1016/j.ijcard.2018.05.031. Epub 2018 Jun 1."},{"pmid":"29414920","type":"DERIVED","citation":"Fastner C, Behnes M, Sartorius B, Wenke A, Lang S, Yucel G, Sattler K, Rusnak J, Saleh A, Barth C, Mashayekhi K, Hoffmann U, Borggrefe M, Akin I. Interventional Left Atrial Appendage Closure Affects the Metabolism of Acylcarnitines. Int J Mol Sci. 2018 Feb 7;19(2):500. doi: 10.3390/ijms19020500."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M9246","name":"Hemorrhage","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]}},"hasResults":false}